Latest News

FDA clears an oral TYK2 blocker for active psoriatic arthritis, delivering strong ACR20 gains with a familiar safety profile.

There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.

EPCORE trials show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed refractory follicular lymphoma with outpatient dosing.

Walgreens pilots hybrid pharmacists—4 days in-store, 1 day remote—seeking less burnout and more steady staffing.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Pharmacists and students must stay up to date on vaccine recommendations amid changing guidelines.

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

Clinical trial insights link talquetamab resistance to GPRC5D loss in multiple myeloma; oncology pharmacy teams can spot escape and refine treatment.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

Post–COVID-19 access gaps fuel unsafe, unregulated Botox and cosmetic injections; trained pharmacists can deliver regulated botulinum toxin injectables through voluntary specialization.

This decision builds upon the drug’s initial approval for adult patients and introduces a new therapeutic option for clinicians treating pediatric populations with rapid heart rate disturbances.

WHI data links radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Emerging therapeutic options represent a new age for treatment of high-risk non-muscle-invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.